Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2007-10-18 Annual Report
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Annual Report to shareholders 54 pages ?Kb
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2007' and contains typical sections of an annual report such as Chairman's Letter, CEO and Operations Review, Directors' Report, Corporate Governance Statement, Auditor's Independence Declaration, Income Statement, Balance Sheet, Cash Flow Statement, Notes to the Financial Statements, Directors' Declaration, and Independent Auditor's Report. The content includes detailed company information, financial statements, strategic overview, and operational highlights for the fiscal year 2007. The length of the document (15,000 characters) and the presence of comprehensive financial and operational data confirm it is the full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2007
2007-10-18 English
Notice of Annual General Meeting/Proxy Form 10 pages ?Kb
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING, EXPLANATORY MEMORANDUM AND PROXY FORM' for HalcyGen Pharmaceuticals Limited. It includes details about the date, time, and place of the AGM, the business to be conducted including consideration of the financial report and directors' and auditor's reports for the year ended 30 June 2007, resolutions for re-election of directors, approval of new issue of options, and adoption of the remuneration report. It also contains an explanatory memorandum providing detailed information about the resolutions to be voted on at the AGM. The document is clearly a notice and explanatory material related to the Annual General Meeting, not the Annual Report itself or any other financial report. It is a meeting notice and proxy solicitation document with explanatory notes, which fits the definition of AGM Information (AGM-R).
2007-10-18 English
Director Appointment 2 pages ?Kb
Board/Management Information Classification · 100% confidence The document is a company announcement dated 17 October 2007 about the appointment of Mr Ian Scholes as a Non-executive Director of HalcyGen Pharmaceuticals Limited. It focuses on management changes and provides background on the company and the new director's experience. There is no financial data, no mention of a report or filing, and the content is clearly about board/management information. The document length is short (2172 characters), and it is not an announcement of a report publication or regulatory filing. Therefore, the appropriate classification is Board/Management Information (MANG).
2007-10-16 English
Full Year Statutory Accounts 55 pages ?Kb
Annual Report Classification · 100% confidence The document is titled 'FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2007' and contains detailed sections typical of a full annual financial report, including a company directory, directors' report, corporate governance statement, auditor's independence declaration, income statement, balance sheet, statement of changes in equity, cash flow statement, notes to the financial statements, directors' declaration, and independent audit report. The content includes comprehensive financial data, management discussion, and governance information for the full fiscal year ending June 30, 2007. This matches the characteristics of an Annual Report (10-K equivalent) rather than a shorter interim report or an announcement. The document length (15,000 characters) and detailed financial statements confirm it is the full report, not just an announcement or summary. Therefore, the correct classification is Annual Report (10-K). FY 2007
2007-09-27 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares held before and after the change, nature of the change, and consideration paid. This is a clear report of personal share transactions by a company director. The document length is 3472 characters, which is consistent with a detailed director's dealing notice. There is no indication that this is an annual report, earnings release, or any other type of filing. Therefore, the document fits the definition of Director's Dealing (DIRS).
2007-09-12 English
Successful Second Clinical Study for SUBA-Itraconazole 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a press release dated 11 September 2007 from HalcyGen Pharmaceuticals announcing the successful results of a second clinical pharmacokinetic study for their anti-fungal drug SUBA-Itraconazole. It discusses clinical trial results, future plans for a Phase III trial, and background on the company and its licensing partnership. There are no financial statements, regulatory filings, voting results, or management changes. The document is a corporate announcement about clinical study progress and product development milestones, not a formal financial or regulatory report. It is not an earnings release, annual report, or interim report. It does not fit into categories like M&A, capital updates, or governance. Given the content and length (under 5,000 characters), this is best classified as a Regulatory Filing (RNS) as a general corporate announcement that does not fit other categories.
2007-09-10 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.